Navigation Links
FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act
Date:2/7/2011

SAN DIEGO, Feb. 7, 2011 /PRNewswire/ -- Genoptix, Inc. (Nasdaq: GXDX) announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") applicable to the cash tender offer by Novartis to purchase all outstanding shares of common stock of Genoptix at USD$25.00 per share.

The termination of the HSR Act waiting period satisfies one of the conditions necessary for the consummation of the tender offer. The tender offer is scheduled to expire at 12:00 midnight, New York City time, on Friday, February 25, 2011 (which is the end of the day on February 25, 2011), unless the tender offer is extended. Consummation of the tender offer remains subject to other customary conditions, including the tender of a majority of the outstanding shares of Genoptix's common stock, determined on a fully diluted basis.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists.  Genoptix is headquartered in Carlsbad, California.

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Genoptix.  The tender offer for shares of Genoptix described in this press release commenced on January 28, 2011.  Novartis has filed a tender offer statement on Schedule TO with the Securities and Exchange Commission (the "SEC") and Genoptix has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC.  Genoptix stockholders and other investors should read these materials carefully because they contain important information, including the terms and conditions of the tender offer.  These materials and any other documents filed
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... DIEGO, Oct. 7 The West Wireless Health ... to Alan Viars, of Videntity, at the Health ... and open source platforms to enable people to ... networks as they work towards achieving health and ...
... 7 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) candidates for the treatment of cancer, ... its randomized, placebo controlled clinical trial evaluating VTX-1463 ... demonstrated that VTX-1463 significantly improved allergy symptoms based ...
Cached Medicine Technology:West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 2West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:8/4/2015)... ... August 04, 2015 , ... School is almost back in session. Parents and ... for the back-to-school scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile ... annual dental checkup. In fact, the dentist recently updated the practice’s surgical suite to ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health Plan is reminding ... immunizations are covered for members under the Healthchek program . , “Many ... with their immunizations may not be allowed to attend when school begins in ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, ... Bruce McCalley joins its executive leadership team as Senior Vice President of Sales ... technology companies and expanding global markets with a special emphasis on the healthcare ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology ... participating in The ISE® Lions’ Den and Jungle Lounge 2015, which will be held ... Vegas. , During the event, eight emerging security vendors, known as “Gazelles,” will go ...
Breaking Medicine News(10 mins):Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4
... release is available in Spanish . U.S. ... laboratory rats fed blueberries or other foods of interest may ... has paved the way to follow-up experiments, Rosalia C. M. ... Rock, Ark., has determined that several indicators of rat mammary ...
... more common disease striking overweight, younger women is the ... where an osteopathic physician is testing the effectiveness of ... Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, ... the brain, specifically in the absence of a tumor. ...
... year, 10,000 pregnant women and up to 200,000 newborn babies ... globe have for years been looking in vain for a ... have found the biochemically weakness of the lethal malaria parasite, ... related malaria. The malaria parasite travels via the spit ...
... with colon cancer that had spread to distant sites found ... drug regimen that was not recommended. Those patients were exposed ... for the drugsof more than $2 million. The study, ... the American Society for Clinical Oncology,s annual meeting in Chicago, ...
... Blocking two tiny molecules of RNA a chemical ... of blood vessels that occurs in degenerative eye disorders, UT ... in the Proceedings of the National Academy of Sciences ... (AMD), a vascular eye disorder that affects nearly 2 million ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
Cached Medicine News:Health News:Mammary gland development of blueberry-fed lab animals studied 2Health News:Researcher tests drug's impact on neurological disease affecting women 2Health News:Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed 2Health News:Many patients with advanced cancers get treatments that won't help 2Health News:Many patients with advanced cancers get treatments that won't help 3Health News:Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: